Synta Pharmaceuticals Corporation

Zhenjian Du

Kevin Paul Foley

Weiwen Ying

Shijie Zhang

Dinesh U Chimmanamada

Lijun Sun

Howard P Ng

David James

Junghyun Chae

Teresa Przewloka

Hao Li

Dan Zhou

Shuzhen Qin

Chi-Wan Lee

Zachary Demko

Keizo Koya

Shoujun Chen

Elena Kostik

James G Barsoum

Yaming Wu

Jun Jiang

Christopher Borella

Takayo Inoue

Minghu Song

Mei Zhang

Teresa Kowalczyk-Przewloka

Mitsunori Ono

Kevin M Foley

Noriaki Tatsuta

Guiqing Liang

Teresa Kowalczyk-Prezewloka

Timothy Korbut

Shije Zhang

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Triazole compounds that modulate Hsp90 activity

Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. Variable Ris an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R. Substituent Ris defined herein.

Imidazole compounds that modulate HSP90 activity

The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating c-Met associated cancers, in a subject in need thereof.

Method for treating proliferative disorders associated with mutations in c-Met

The invention relates to compounds of structural formula (I): 

Compounds for the treatment of proliferative disorders

Triazone compounds that modulate HSP90 activity

Triazole compounds that modulate HSP90 activity

The present invention relates to compounds that inhibit the activity of Hsp90 and inhibit topoisomerase II.

Method for inhibiting topoisomerase II

The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating Bcr-Abl, FLT-3, EGFR, c-Kit, B-raf, and NPM-ALK associated cancers, in a subject in need thereof.

Method for treating a B-raf associated cancer with an Hsp90 inhibitor

Pyrazole compounds that modulate HSP90 activity

Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell Variable Ris an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R. Substituent Ris defined herein.

Growing community of inventors

Northborough, MA, United States of America

Zhenjian Du